Regeneron (REGN) - News Mentions

Sign up to add (REGN) to your portfolio and access more historical data.

30%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 2 100%
Gilead Sciences
Gilead Sciences
GILD		 2 33.3%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 1 0%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 0 0%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 0 0%
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report– Hagens Berman
January 22
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
January 22
Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
January 22
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
January 22
REGENERON PHARMACEUTICALS SECURITIES FRAUD NOTICE: Berger Montague Informs Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of Securities Fraud Lawsuit
January 21
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – REGN
January 21
Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
January 21
INVESTOR REMINDER: Berger Montague Notifies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of a Class Action Lawsuit and Deadline
January 21
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
January 21
Aaron Wealth Advisors LLC Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
January 21
HB Wealth Management LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
January 21
REGN Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
January 21
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
January 20
Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
January 20
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report – Hagens Berman
January 20
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
January 19

Month over Month

Est. daily news mentions.

Dec 2024 1
Nov 2024 1
Oct 2024 1
Sep 2024 1
Aug 2024 1

How often is Regeneron mentioned in the news?

Regeneron was mentioned an estimated 3 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Regeneron performing compared to its industry peers?

Regeneron overperforms a majority of its industry peers when it comes to News Mentions, ranking in the 75th percentile.

Has there been an increase or decrease in news mentions of Regeneron in the last month?

There has been no significant change in the number of news mentions for Regeneron's compared to the last month.

Why is it important to track news mentions for Regeneron?

By monitoring mentions in the news for Regeneron, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Regeneron, ultimately improving their investment strategies.

Sign up and get more insights on Regeneron.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact